Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Return on Capital Employed (2016 - 2026)

Ani Pharmaceuticals' Return on Capital Employed history spans 14 years, with the latest figure at 9.69% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 964.0% to 9.69% in Q4 2025 year-over-year; TTM through Dec 2025 was 9.69%, a 964.0% increase, with the full-year FY2025 number at 10.25%, up 1018.0% from a year prior.
  • Return on Capital Employed hit 9.69% in Q4 2025 for Ani Pharmaceuticals, up from 6.51% in the prior quarter.
  • Over the last five years, Return on Capital Employed for ANIP hit a ceiling of 9.69% in Q4 2025 and a floor of 9.17% in Q3 2022.
  • Historically, Return on Capital Employed has averaged 0.05% across 5 years, with a median of 0.32% in 2025.
  • Biggest five-year swings in Return on Capital Employed: tumbled -779bps in 2022 and later soared 1485bps in 2023.
  • Tracing ANIP's Return on Capital Employed over 5 years: stood at 7.46% in 2021, then grew by 27bps to 5.43% in 2022, then soared by 215bps to 6.25% in 2023, then crashed by -99bps to 0.05% in 2024, then skyrocketed by 18015bps to 9.69% in 2025.
  • Business Quant data shows Return on Capital Employed for ANIP at 9.69% in Q4 2025, 6.51% in Q3 2025, and 1.41% in Q2 2025.